Regeneron Highlights Scientific Innovation And Leadership In Respiratory Disease Management At ERS 2024, Featuring Dupixent And Itepekimab
Regeneron Highlights Scientific Innovation And Leadership In Respiratory Disease Management At ERS 2024, Featuring Dupixent And Itepekimab
Regeneron在ERS 2024上突出了呼吸系統疾病管理方面的科學創新和領導地位，重點介紹了Dupixent和Itepekimab
- 20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
- Data from landmark Phase 3 trials for Dupixent in COPD reinforce exacerbation reduction and improvement in lung function compared to placebo, and provide new assessments on health-related quality of life across patient subgroups
- Additional presentations spotlight a novel asthma imaging study showing the early impact of Dupixent on clinical remission, airway remodeling and mucus plugging starting at 4 weeks, as well as data from investigational therapy itepekimab in former smokers with COPD
- 提供20份摘要，包括4個口頭報告，爲慢性阻塞性肺疾病（COPD），哮喘和慢性鼻竇炎合併鼻息肉（CRSwNP）的治療提供新的見解。
- 從Dupixent在COPD的重要第3期試驗數據強化了減少惡化和改善肺功能的效果，併爲患者亞組的健康相關生活質量提供了新的評估。
- 其他報告重點介紹了一項新穎的哮喘成像研究，顯示Dupixent對臨床緩解，氣道重塑和黏液堵塞的早期影響從4周開始，以及來自治療候選藥itepekimab在老菸民患者中的COPD數據。